机构:[1]Department of Clinical Pharmacology, Pharmacy Care Center, Chinese PLA General Hospital, Beijing 100853, P.R. China.[2]Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing 100053, P.R. China.药剂科[3]Department of Pharmacology and System Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA.
Depression is often triggered by prolonged exposure to psychosocial stressors and associated with coronary heart disease (CHD). Matrix metalloproteinases (MMPs) are involved in the pathogenesis of various emotional and cardiovascular disorders. The purpose of this study was to investigate whether Kai‑Xin‑San (KXS), which may terminate the signaling of MMPs, exerts antidepressant‑like and cardioprotective effects in a myocardial infarction (MI) plus depression rat model. Rats were randomly assigned to five groups: A normal control (control group), a celisc‑injection of isopropyl adrenaline group (ISO group), depression (depression group), an ISO + depression (depression + ISO group), and an ISO + depression group treated with intragastric administration of 1,785 mg/kg KXS (KXS group). Behavioral changes, echocardiography, biochemical index, matrix metalloproteinase (MMP) and apoptosis‑related proteins were assessed. Compared with the depression + ISO group, KXS significantly improved stress‑induced alterations of behavioral parameters and protected the heart by enlarging the left ventricular (LV) fractional shortening (FS) and LV ejection fraction (EF). Moreover, KXS significantly attenuated ISO + depression‑induced MMP‑2 and MMP‑9 expression at the mRNA and protein level and decreased TIMP in the heart compared to the complex model group. Myocardial apoptosis was significantly attenuated by KXS by regulating the Bcl‑2/Bax axis. These results indicated that MI comorbid with depression may damage the MMP balance in the central and peripheral system, and KXS may have a direct anti‑depressive and cardio‑protective effect by regulating the level of MMPs and associated myocardial apoptosis. It is promising to further explore the clinical potential of KXS for the therapy or prevention of MI plus depression comorbidity disease.
第一作者机构:[1]Department of Clinical Pharmacology, Pharmacy Care Center, Chinese PLA General Hospital, Beijing 100853, P.R. China.
通讯作者:
通讯机构:[1]Department of Clinical Pharmacology, Pharmacy Care Center, Chinese PLA General Hospital, Beijing 100853, P.R. China.
推荐引用方式(GB/T 7714):
Hu Yuan,Dong Xianzhe,Zhang Tianyi,et al.Kai‑Xin‑San suppresses matrix metalloproteinases and myocardial apoptosis in rats with myocardial infarction and depression.[J].Molecular medicine reports.2020,21(1):508-516.doi:10.3892/mmr.2019.10807.
APA:
Hu Yuan,Dong Xianzhe,Zhang Tianyi,Ma Hongming,Yang Wenshan...&Chen Yibang.(2020).Kai‑Xin‑San suppresses matrix metalloproteinases and myocardial apoptosis in rats with myocardial infarction and depression..Molecular medicine reports,21,(1)
MLA:
Hu Yuan,et al."Kai‑Xin‑San suppresses matrix metalloproteinases and myocardial apoptosis in rats with myocardial infarction and depression.".Molecular medicine reports 21..1(2020):508-516